Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma

University of Cologne

Status and phase: Terminated; Phase 2

Conditions: Hodgkin Disease

Treatments: Drug: Bortezomib; Drug: Dexamethasone

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00148018

X05132

Details and patient eligibility

About

The primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed Hodgkin's lymphoma.

Full description

The proteasome-inhibitor bortezomib (Velcade) shows promising activity in various human lymphoma cell line. In addition, several studies in heavily pretreated patients with lymphoma showed also promising results.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hodgkin's lymphoma
• Second or higher relapse (first relapse if high-dose chemotherapy not possible)
• Age >/= 18 years
• No major organ dysfunction or intercurrent disorder
• Written informed consent

Exclusion criteria

• Pregnant or nursing

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)